Labeling Antibodies with 32P for Cancer Treatment
Author Information
Author(s): B.M.J. Foxwell, H.A. Band, J. Long, W.A. Jeffery, D. Snook, P.E. Thorpe, G. Watson, P.J. Parker, A.A. Epenetos, A.M. Creighton
Primary Institution: Imperial Cancer Research Fund
Hypothesis
Can a novel method for phosphorylating antibodies improve their use in cancer therapy?
Conclusion
The developed method allows for efficient phosphorylation of antibodies without compromising their binding activity.
Supporting Evidence
- The method allows high specific activities to be achieved without impairing antibody function.
- Phosphorylated antibodies were stable in human, mouse, and rat plasmas in vitro.
- The half-life of the conjugate in mice was found to be 2 days, which is faster than native antibodies.
Takeaway
Scientists found a new way to attach a special marker to antibodies that helps them fight cancer better, and it doesn't make them less effective.
Methodology
The study involved chemically linking a synthetic peptide to antibodies and then phosphorylating them using protein kinases.
Limitations
The study does not address the long-term effects of the conjugated antibodies in vivo.
Want to read the original?
Access the complete publication on the publisher's website